Impact of Leflunomide Versus Biologic Agents on the Costs of Care for Rheumatoid Arthritis in a Managed Care Population

Daniel A. Ollendorf, MPH;Anna N. Peterson, BA;Joseph Doyle, RPh, MBA;Daniel M. Huse, MA;

.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Impact of Leflunomide Versus Biologic Agents on the Costs of Care for Rheumatoid Arthritis in a Managed Care Population

May 1, 2002

Daniel A. Ollendorf, MPH, Anna N. Peterson, BA, Joseph Doyle, RPh, MBA, Daniel M. Huse, MA

Supplements and Featured Publications, Cost and Utilization Analysis for Rheumatoid Arthritis Treatments: An Update for Managed Care, Volume 8, Issue 7 Suppl